Reuters: Health
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.
Novartis arthritis drug falls short in challenge to global bestseller
Novartis arthritis drug falls short in challenge to global bestseller
Reuters: Health
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.
Reuters: Health
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment